Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shield Therapeutics ( (GB:STX) ) has issued an update.
Shield Therapeutics plc has launched ACCRUFeR® in Canada, marking it as the only prescription-only oral treatment for iron deficiency anemia in the country. This launch is in partnership with Kye Pharmaceuticals and follows Health Canada’s approval in August 2024. The collaboration allows Shield to receive milestone payments and royalties based on sales. The introduction of ACCRUFeR® provides a new treatment option for Canadians, addressing a public health concern affecting a significant portion of the population. This expansion strengthens Shield’s global market presence and offers a valuable alternative to existing iron therapies, potentially impacting patient care positively.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial stage specialty pharmaceutical company that focuses on delivering innovative treatments for iron deficiency, with or without anemia. Their primary product, ACCRUFeR® (ferric maltol), addresses significant unmet medical needs and is commercialized in various regions including the U.S., UK, European Union, and Canada through partnerships with other pharmaceutical companies.
YTD Price Performance: 22.22%
Average Trading Volume: 2,443,657
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £34.38M
Find detailed analytics on STX stock on TipRanks’ Stock Analysis page.